Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicenter survey of the Italian CF Society  by Colombo, C. et al.
5. Microbiology S37
141* Pulmonary exacerbations in adult patients with cystic ﬁbrosis
associated with positive viral PCR
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Introduction: Studies show the prevalence of respiratory viruses in patients
(pts) with cystic ﬁbrosis (CF) and increased respiratory symptoms ranges from
13% to 52% and infection is associated with increased morbidity. Given the recent
H1N1 pandemic we investigate the clinical impact of positive virus isolates in adult
CF pts with an exacerbation.
Method: We routinely undertake throat swabs for viral PCR in all pts starting
i.v antibiotics (abx). A retrospective analysis of all pts receiving i.v abx for an
exacerbation between 01/12/08 and 01/12/09 was undertaken. Pts with positive viral
PCR were compared to negative controls. Exclusion criteria included pregnancy,
transplant and continuous I.V. therapy.
Results: A total of 42 pts (median age 26.5) had positive viral PCR (overall
prevalence 9.5%), with 7 having H1N1. Negative PCR occured in 440 IV courses
(189 pts). The 1st course of treatment for each patient was used as a control.
Positive PCR was associated with a signiﬁcantly worse baseline lung function and
weight with a higher proportion of pts on enteral feed. The viral group had a
higher CRP (p< 0.05), wcc (p< 0.05) and neutrophil count (p< 0.05) at the start
of treatment. Viral infection was associated with a greater drop in FEV1 between
pre exacerbation baseline and end of treatment in comparison to controls.
Duration of Change with treatment
treatment (d) %FEV1 FEV1 %FVC FVC CRP Weight
Control 14 5% 0.16 L 5.5% 0.19 L 2.15 0.4kg
Virus 18 2% 0.065 L 0 0 16.65 −0.05 kg
p 0.0018 0.0101 0.0159 0.0446 0.1756 0.0002 0.0142
Conclusion: Pulmonary exacerbations with viral infections are associated with a
greater inﬂammatory response, longer duration of treatment and greater impact on
lung function.
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Introduction: Previous studies suggest adult patients (pts) with cystic ﬁbrosis (CF)
who have viruses isolated at exacerbation have an increased length of treatment
and morbidity. Given the recent H1N1 pandemic we report the clinical impact of
positive viral isolates on exacerbations in adult pts with CF.
Method: Our unit has routinely performed surveillance throat swabs for viral
PCR before treatment for an exacerbation. We retrospectively analysed all pts with
positive PCR between 1/12/08 and 1/12/09. Data from pts who were pregnant, post
lung transplant or on continuous i.v. antibiotic therapy were excluded. Data was
analysed using the Mann–Whitney U test with a p value of <0.05 being signiﬁcant.
Results: Over a 12 month period there were 42 viral isolates identiﬁed in 440
exacerbations in 189 pts (9.5% prevalence). There were 29 rhinovirus, 1 aden-
ovirus & rhinovirus, 7 H1N1 & 5 other viruses. Peak incidence of H1N1 was
between Sept and Nov 2009. In all pts with positive PCR there was no signiﬁcant
improvement in lung function at the end of treatment and there was a signiﬁcant
decrease in their end of treatment lung function (FEV1 and FVC) when compared
to pre-exacerbation baseline. When comparing Rhinovirus pts with all other viral
pts there was no signiﬁcant difference in length of treatment, improvement in lung
function, increase in weight or change in inﬂammatory markers. When comparing
H1N1 pts with all other viruses the only signiﬁcant difference was a higher starting
CRP (p< 0.05) and the change in CRP with treatment (p< 0.05).
Conclusion: H1N1 exacerbations were not associated with increased length of
treatment or morbidity in comparison to other viral exacerbations.
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Aim: The aim of this survey was to characterize the impact of 2009 pandemic inﬂuenza
A (H1N1) in the Italian CF population.
Methods: A questionnaire was sent to the 34 Italian CF Centers to collect data of
patients who had presented suggestive symptoms and tested positive for A/H1N1 virus
at nasopharyngeal swab (RT-PCR).
Results: Overall 64 cases with conﬁrmed A/H1N1 infection were reported from 17
Centers. Among the 64 patients positive to A/H1N1 virus, there were 38 males (59%),
median age was 14 yrs (range 0.5−39). Median FEV1 was 58.5% predicted (range 12–
134); 43 of the patients (67%) had preexisting chronic infection by P. aeruginosa or
other Gram negative bacteria; 3 patients had undergone organ transplantation and were
on immunosuppressive treatment. Four patients had received one dose of the speciﬁc
vaccine within 2 weeks of inﬂuenza onset. After diagnosis, all patients were treated
with oseltamivir for a median period of 5 days. Inﬂuenza had a median duration of
5.5 days and was uncomplicated in 21 cases (33%), including the 3 CF patients on
immunosuppressive treatment. In 31 patients FEV 1 was assessed one month after
recovery and was not signiﬁcantly different from values recorded before inﬂuenza.
However, during the course of the illness pulmonary exacerbation occurred in 43 pa-
tients (67%). Other complications included late resolution pneumonia (2 patients) and
long term need for oxygen therapy (1 patient); 3 patients with severe pulmonary disease
(FEV1< 30%) died of respiratory failure.
Conclusions: Complications from inﬂuenza A/H1N1 occur frequently in CF and in a
few patients may be quite severe.
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Introduction: The role of Rhinovirus as a cause of exacerbations in adults with CF
is unclear. We reviewed the outcome for adult patients with CF who had a sputum
positive PCR result for Rhinovirus infection.
Methods: Sputum samples were sent from patients presenting with symptoms of
a corzyal illness during 2009 and investigated using an in-house PCR method to
detect Rhinovirus. Permission for the study was granted by the local medical ethics
committee.
Results: 12 of 52 patients had Rhinovirus detected in their sputum. Of the 12
patients with Rhinovirus isolated from sputum: 6 = male, 6 = female, median age =
29 years (range 19−68 years). 4 were treated with additional oral antibiotics and
not hospitalised, and 8 were treated with intravenous antibiotics, 7 of whom were
hospitalised.
Mean (SD) %FEV1 at presentation = 42.6% (21.0), at end of treatment =
48.2% (19.5) (p = 0.042). Mean (SD) %FVC at presentation = 58.3% (18.7), at
end of treatment = 67.2% (20.0) (p = 0.008).
The admitted patients spent mean (SD) 14.4 (8.2) days in hospital on IVs and 15.1
(7.7) days on IVs in total. Six of the 7 admitted patients had blood tests pre and post
treatment, with mean (SD) CRP = 58.8 (43.8) at admission, 14.08 (14.1) at discharge
(p = 0.074), mean (SD) lymphocyte count 1.31 (0.57) at admission, 1.61 (0.63)
at discharge (p = 0.169), mean (SD) neutrophil count 9.62 (3.59) at admission,
7.06 (2.18) at discharge (p = 0.150), mean (SD) total wcc count 12.1 (4.00) at
admission, 7.06 (2.18) at discharge (p = 0.329).
Conclusions: Rhinovirus was associated with clinical symptoms of exacerbations
among this group of adult patients with CF.
